within Pharmacolibrary.Drugs.ATC.V;

model V04CG04
  extends Pharmacokinetic.Models.PK_1C(
    weight         = 70,
    F              = 1,
    Cl             = 0.0008333333333333334,
    adminDuration  = 600,
    adminMass      = 6 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0002,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>V04CG04</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Pentagastrin is a synthetic peptide that mimics the actions of gastrin, stimulating gastric acid secretion and pepsin production, and is primarily used as a diagnostic agent in tests of gastric function. It is not widely used therapeutically and has largely been replaced by other diagnostic methods.</p><h4>Pharmacokinetics</h4><p>No direct human pharmacokinetic model or validated parameters could be identified in the scientific literature for pentagastrin. Available published literature focuses mainly on its pharmacodynamic effects and diagnostic use, rather than PK modeling. Below are rough estimates based on the drug’s peptide structure, rapid onset of action following injection, and physicochemical properties.</p><h4>References</h4><ol><li><p>Keating, GM, &amp; Figgitt, DP (2004). Intravenous esomeprazole. <i>Drugs</i> 64(8) 875–883. DOI:<a href=\"https://doi.org/10.2165/00003495-200464080-00008\">10.2165/00003495-200464080-00008</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/15059043/\">https://pubmed.ncbi.nlm.nih.gov/15059043</a></p></li><li><p>Simon, B, et al., &amp; Wurst, W (1990). Single intravenous administration of the H+, K(+)-ATPase inhibitor BY 1023/SK&amp;F 96022--inhibition of pentagastrin-stimulated gastric acid secretion and pharmacokinetics in man. <i>Alimentary pharmacology &amp; therapeutics</i> 4(3) 239–245. DOI:<a href=\"https://doi.org/10.1111/j.1365-2036.1990.tb00468.x\">10.1111/j.1365-2036.1990.tb00468.x</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/1966542/\">https://pubmed.ncbi.nlm.nih.gov/1966542</a></p></li><li><p>Freston, JW, et al., &amp; Lee, CQ (2004). Evaluation of the pharmacokinetics and pharmacodynamics of intravenous lansoprazole. <i>Alimentary pharmacology &amp; therapeutics</i> 19(10) 1111–1122. DOI:<a href=\"https://doi.org/10.1111/j.1365-2036.2004.01942.x\">10.1111/j.1365-2036.2004.01942.x</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/15142201/\">https://pubmed.ncbi.nlm.nih.gov/15142201</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end V04CG04;
